Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      TSO3 Reports Third Quarter 2018 Results


      News provided by

      TSO3 Inc.

      Nov 06, 2018, 18:16 ET

      Share this article

      Share this article


      QUEBEC CITY and MYRTLE BEACH, SC, Nov. 6, 2018 /PRNewswire/ - TSO3 Inc. (TSX: TOS) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, reported financial results for the third fiscal quarter ended September 30, 2018.

      Business Highlights

      In the third quarter of 2018, TSO3 shipped four STERIZONE® VP4 Sterilizers to end users.  As of November 6, 2018, a cumulative 68 STERIZONE® VP4 Sterilizers have been shipped to end users (59 installed, nine to be installed). In addition, the Company has a further 22 units of backlog for future shipments through customer purchase orders or commitments, ten of which were received subsequent to the end of the quarter and were directly related to TSO3 only activity.  The Company now has a total of 90 sterilizers either installed, to be installed or committed to be shipped.

      On August 1, 2018, TSO3 announced that it and a fund of which Courage Capital Management LLC, ("Courage") is the investment advisor, entered into a binding US$20 million debt financing to fund commercialization initiatives for its STERIZONE® VP4 Sterilizer.  Courage is a Nashville, TN headquartered alternative asset management firm with a 20-year track record of investments in health care services, medical devices, and pharmaceuticals. 

      Concurrent with the Courage financing, TSO3 and Getinge mutually decided not to renew the distribution agreements that had existed between the parties and agreed to provide TSO3 unrestricted independent commercialization of its STERIZONE® VP4 Sterilizers, enable the Company's purchase of STERIZONE® VP4 Sterilizers from Getinge and transition the existing sales pipeline along with the service, maintenance and consumables sales of all existing STERIZONE® VP4 Sterilizer customers in the United States and Canada to TSO3. 

      "TSO3 has established a goal to ship or receive commitments for 200 STERIZONE® VP4 Sterilizers by the end of 2019", stated R.M. (Ric) Rumble, President and CEO of TSO3. "We have now purchased the inventory we need at favourable pricing, raised capital and hired and trained a team of experienced sales and service personnel in support of this goal."

      2018 Third Quarter Financial Summary

      • Revenues equaled $0.8 million, as compared to $0.4 million in the second quarter of 2018 and $5.1 million in the third quarter of 2017. TSO3 revenues in the third quarter of 2018 reflect sales of sterilizers, consumables, accessories and service parts.  The Company shipped four sterilizers to hospitals in the third quarter of 2018 as opposed to 44 sterilizers to its former distributor in the same period last year. 
      • Gross profit was $1.2 million, as compared to $0.1 million in the second quarter of 2018 and $2.0 million in the third quarter of 2017.  The Company generated gross profit from sales of sterilizers, consumables, accessories and service parts. Gross profit includes a $0.8 million reversal of the warranty provision associated with inventory purchased from the Company's former distributor.
      • Financial income was $0.6 million, as compared to immaterial amounts in both the second quarter of 2018 and third quarter of 2017. The Company recorded $0.5 million of accrued interest expense related to a $20.0 million debt financing it obtained on August 1, 2018 and a non-cash gain of $1.1 million on the revaluation of the embedded derivative within the Convertible Note associated with this financing.   
      • The Company's net loss was $(2.1) million or $(0.02) per share in the third quarter of 2018, as compared to $(4.0) million, or $(0.04) per share, in the second quarter of 2018 and to $(1.8) million or $(0.02) per share in the year-ago quarter.
      • The Company had $16.1 million in cash, cash equivalents and investments as of September 30, 2018, as compared to $14.8 million at the end of 2017.  In the third quarter of 2018, the Company raised $20 million in debt financing ($19.7 million net of expenses) and used $1.7 million for operations excluding changes in non-cash working capital, and $8.7 million for changes in non-cash working capital, which includes $7.9 million used for the repurchase of 230 STERIZONE® VP4 Sterilizers and associated accessories from its former distribution partner. 
      • Inventories were $4.0 million as of September 30, 2018, as compared to $2.0 million at the end of 2017. During the third quarter of 2018, the Company bought 230 sterilizers and associated accessories for $7.9 million from its former distributor and applied an unamortized $6.0 million balance of deferred license fees associated with its former distribution agreement to these repurchased units.  In addition, the Company also applied the repurchase provision of $0.5 million it recorded in the second quarter of 2018 in relation to the upgrades of 47 STERIZONE® VP4 sterilizers against finished goods.

      Supplemental Non-IFRS Financial Measures

      In addition to IFRS financial measures, management uses non-IFRS financial measures to assess the Company's operational performance. It is likely that the non-IFRS financial measures used by the Company will not be comparable to similar measures reported by other issuers or those used by financial analysts as their measures may have different definitions. The measures used by the Company are intended to provide additional information and should not be considered in isolation or as a substitute for IFRS financial performance measures.

      Generally, a non-IFRS financial measure is a numerical measure of an entity's historical or future financial performance, financial position or cash flows that is neither calculated nor recognized under IFRS. Management believes that such non-IFRS financial measures are important as they provide users of the financial statements with a better understanding of the results of the Company's recurring operations and their related trends, while increasing transparency and clarity into its operating results. Management also believes these measures can be useful in assessing the Company's capacity to discharge its financial obligations.

      Management is assessing its operational performance using supplemental non-IFRS measures which remove significant unusual items that do not reflect the recurring and ongoing operating results and trends.

      Additional Third Quarter 2018 Financial information




      $000's

      2018

      2017

      Q3

      Q2

      Q1

      Q4

      Q3

      Q2

      Q1

      Net loss

      (2,104)

      (3,952)

      (4,512)

      (1,449)

      (1,771)

      (2,254)

      (1,980)

      Financial expenses (income)

      (599)

      (12)

      (14)

      74

      48

      49

      (39)

      Amortization and depreciation

      270

      292

      315

      246

      331

      221

      168

      Share-based compensation expense

      688

      627

      371

      301

      632

      592

      609

      Income taxes

      11

      7

      -

      (59)

      33

      29

      27

      Adjusted Ebitda

      (1,734)

      (3,038)

      (3,840)

      (887)

      (727)

      (1,363)

      (1,215)

      Adjusted EBITDA is adjusted Earnings before Interest, Taxes, Depreciation, and Amortization (Adjusted EBITDA). Adjusted EBITDA adjusts net income for (1) significant realized and unrealized foreign exchange gains or losses, (2) financial expenses (income), (3) amortization and depreciation expenses (4) share-based compensation expense, (5) write-downs of certain tangible and intangible assets, (6) one-time write-off of inventory, (7) income taxes, and (8) other significant unusual items.

      Summary of Results
      Periods ended September 30, 2018 and 2017 (Unaudited, IFRS Basis, in thousands of US dollars, except per share amounts)





      Third Quarter

      Nine months


      2018

      $

      2017

      $

      2018

      $

      2017

      $

      Revenues

      782

      5,105

      1,410

      13,946

      Cost of sales

      (394)

      3,102

      451

      8,613


      1,176

      2,003

      959

      5,333

      Expenses





      Research and development

      1,260

      1,562

      4,452

      4,456

      Selling, general and administrative

      2,608

      2,131

      7,681

      6,735

      Financial (income) expenses

      (599)

      48

      (624)

      58

      Total Expenses

      3,269

      3,741

      11,509

      11,249

      Net loss before income taxes

      (2,093)

      (1,738)

      (10,550)

      (5,916)

      Income taxes

      11

      33

      18

      89

      Net loss and comprehensive loss

      (2,104)

      (1,771)

      (10,568)

      (6,005)

      Weighted average number of outstanding shares

      (in thousands)

      93,208

      92,842

      93,009

      92,258

      Basic and diluted net loss per share

      (0.02)

      (0.02)

      (0.11)

      (0.07)

      Basic and diluted net comprehensive loss per share

      (0.02)

      (0.02)

      (0.11)

      (0.07)

      Interim Consolidated Statements of Financial Position
      (Unaudited, in thousands of US dollars)





      September 30,
      2018
      $

      December 31,
      2017
      $

      Current Assets



      Cash and Cash Equivalents

      16,082

      8,044

      Short-term Investments

      -

      6,764

      Accounts Receivable

      855

      651

      Inventories

      3,976

      2,040

      Prepaid Expenses

      238

      150


      21,151

      17,649

      Non-current Assets



      Property, Plant and Equipment

      2,592

      3,184

      Intangible Assets

      1,839

      1,886


      4,431

      5,070


      25,582

      22,719

      Current Liabilities



      Accounts Payable and Accrued Liabilities

      2,055

      2,430

      Warranty Provision

      251

      1,263

      Current Tax Liabilities

      11

      68

      Deferred Revenues

      16

      6


      2,333

      3,767

      Non-current Liabilities



      Deferred Tax Liabilities    

      17

      17

      Debt

      17,364

      -

      Embedded Derivative

      1,693

      -

      Deferred Revenues

      -

      6,044


      21,407

      9,828

      Equity



      Share Capital

      111,471

      111,215

      Reserve – Share-based Compensation

      8,170

      6,574

      Deficit

      (113,754)

      (103,186)

      Accumulated Other Comprehensive Loss

      (1,712)

      (1,712)


      4,175

      12,891


      25,582

      22,719

      Interim Consolidated Statements of Cash Flows
      As of September 30, 2018, and 2017 (Unaudited, in thousands of US dollars)




      Nine months


      2018

      $

      2017

      $

      Cash flows from operating activities



      Net loss

      (10,568)

      (6,005)

      Adjustments for:



      Depreciation and amortization

      877

      715

      Loss on write-down of property, plant and equipment

      66

      39

      Deferred income tax liabilities

      -

      89

      Share-based compensation

      1,686

      1,833

      Capitalized interest on long term debt

      445

      -

      Embedded derivative (gain) recognized in net loss

      (1,103)

      -

      Investment income

      (69)

      (138)


      (8,666)

      (3,467)

      Changes in non-cash operating working capital items

      (9,772)

      883

      Interest received

      106

      127

      Cash flows used in by operating activities

      (18,332)

      (2,457)

      Cash flows from investing activities



      Acquisition of investments

      -

      (2,909)

      Disposal of investments

      6,726

      11,015

      Acquisition of property, plant and equipment

      (136)

      (1,057)

      Acquisition of intangible assets

      (102)

      (190)

      Proceed from disposal of property, plant and equipment

      -

      2

      Cash flows generated by investing activities

      6,488

      6,861

      Cash flows from financing activities    



      Issuance of debt net of financing fees

      19,666

      -

      Financing fee recognized in net loss

      50

      -

      Options exercised

      166

      540

      Cash flows generated by financing activities

      19,882

      540

      Increase in cash and cash equivalents

      8,038

      4,944

      Cash and cash equivalents at the beginning

      8,044

      2,698

      Cash and cash equivalents at the end

      16,082

      7,642

      Results Conference Call

      Date: Wednesday, November 7, 2018
      Time: 8:30 a.m. EST
      Toll-free dial-in number: 1-888-231-8191
      International dial-in number: 1-514-807-9895 (Montreal); 1-647-427-7450 (Toronto)
      Conference ID: 4598474

      Analysts and investors are invited to participate to the call. Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting to the conference call, please contact Gilmartin Group at 1-610-368-6505.  

      Other interested parties may listen to the live webcast of the conference call at https://event.on24.com/wcc/r/1863190/0A8CDB0936AF81795D977C263FE1FCCC which will be available for replay in the Investors section of the Company's website at www.tso3.com.         

      About the STERIZONE® VP4 Sterilizer

      The STERIZONE® VP4 Sterilizer is a low-temperature sterilization system that utilizes the dual sterilants of vaporized hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilization of heat and moisture-sensitive medical devices. Its single pre-programmed cycle can sterilize a large number and wide range of compatible devices, creating a cost-effective sterilization process with error-free cycle selection. The device's unique Dynamic Sterilant Delivery System™ automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. This capability removes the guesswork and potential for human error, as there is no need to sort instruments and choose the appropriate cycles as with other machines.

      The STERIZONE® VP4 Sterilizer is the only terminal sterilization method that is FDA cleared to sterilize multi-channeled flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length, such as video colonoscopes, duodenoscopes and gastroscopes - an industry first for any medical device sterilization process.

      The STERIZONE® VP4 Sterilizer is also the only cleared low temperature sterilizer that can process a mixed load consisting of general instruments, single channel flexible endoscopes, and single or double channel rigid endoscopes in the same cycle with load weights of up to 75 lb.  The ability to run mixed loads significantly reduces labor costs by minimizing the amount of instrument sorting required, while maximizing the device turns (more productivity from increased throughput capacity).

      More information about the STERIZONE® VP4 Sterilizer is available through TSO3's website, under the Products section.

      About TSO3

      Founded in 1998, TSO3's activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3 also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

      For more information about TSO3, visit the Company's website at www.tso3.com.

      The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, the limited history of sales or distribution of the Company, the ability of the Company to obtain the required regulatory clearances to market its products, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. Although TSO3 believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The complete versions of the cautionary note regarding forward-looking statements as well as a description of the relevant assumptions and risk factors likely to affect TSO3's actual or projected results are included in the Management's Discussion and Analysis for the year ended December 31, 2017, which is available on the Company's website. The forward-looking statements contained in this press release are made as of the date hereof, and TSO3 does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise unless expressly required by applicable securities laws.

      SOURCE TSO3 Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.